[go: up one dir, main page]

MEP20608A - Sterilne formulacije modifikatora imunskog odgovora i postupci dobijanja - Google Patents

Sterilne formulacije modifikatora imunskog odgovora i postupci dobijanja

Info

Publication number
MEP20608A
MEP20608A MEP-206/08A MEP20608A MEP20608A ME P20608 A MEP20608 A ME P20608A ME P20608 A MEP20608 A ME P20608A ME P20608 A MEP20608 A ME P20608A
Authority
ME
Montenegro
Prior art keywords
immune response
processing procedures
response modifier
imidazo
modifier formulations
Prior art date
Application number
MEP-206/08A
Other languages
Bosnian (bs)
English (en)
Inventor
James D Stoesz
Alexis S Statham
Myhanh T Truong
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP20608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of MEP20608A publication Critical patent/MEP20608A/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A61L2103/05—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
MEP-206/08A 2006-07-31 2007-07-17 Sterilne formulacije modifikatora imunskog odgovora i postupci dobijanja MEP20608A (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82087606P 2006-07-31 2006-07-31

Publications (1)

Publication Number Publication Date
MEP20608A true MEP20608A (hr) 2010-06-10

Family

ID=38617896

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-206/08A MEP20608A (hr) 2006-07-31 2007-07-17 Sterilne formulacije modifikatora imunskog odgovora i postupci dobijanja

Country Status (24)

Country Link
US (1) US8124096B2 (hr)
EP (1) EP1891953B1 (hr)
AR (1) AR062121A1 (hr)
AT (1) ATE532511T1 (hr)
AU (1) AU2007279376B2 (hr)
CA (1) CA2659733A1 (hr)
CL (1) CL2007002228A1 (hr)
CY (1) CY1112264T1 (hr)
DK (1) DK1891953T3 (hr)
ES (1) ES2375744T3 (hr)
HR (1) HRP20120128T1 (hr)
IL (1) IL184652A (hr)
ME (1) MEP20608A (hr)
NO (1) NO338958B1 (hr)
PE (1) PE20080523A1 (hr)
PL (1) PL1891953T3 (hr)
PT (1) PT1891953E (hr)
RS (2) RS52120B (hr)
RU (1) RU2474425C2 (hr)
SI (1) SI1891953T1 (hr)
UA (1) UA93496C2 (hr)
UY (1) UY30513A1 (hr)
WO (1) WO2008016475A2 (hr)
ZA (1) ZA200900618B (hr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
NZ545412A (en) * 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
MY146124A (en) 2003-10-03 2012-06-29 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
US7943609B2 (en) * 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
JP5122980B2 (ja) 2005-02-09 2013-01-16 スリーエム イノベイティブ プロパティズ カンパニー アルキルオキシ置換チアゾロキノリン類およびアルキルオキシ置換チアゾロナフチリデン類
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EP1922317A4 (en) 2005-09-09 2009-04-15 Coley Pharm Group Inc N- {2-Ý4-AMINO-2- (ETHOXYMETHYL) -1H-IMIDAZOÝ4,5-CQUINOLIN-1-YL-1,1-DIMETHYLTHYL} METHANESULFONAMIDE AMIDE AND CARBAMATE DERIVATIVES AND RELATED METHODS
US8088790B2 (en) 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
MX2011001555A (es) 2008-12-19 2011-04-14 Graceway Pharmaceuticals Llc Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica.
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
EP2453747B1 (en) 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
PT2606047T (pt) 2010-08-17 2017-04-07 3M Innovative Properties Co Composições, formulações e métodos de um composto lipidado modificador da resposta imunitária
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
CN103582640B (zh) 2011-06-03 2015-11-25 3M创新有限公司 肼基1h-咪唑并喹啉-4-胺以及由其制成的缀合物
US20160158393A1 (en) * 2014-02-21 2016-06-09 Avadim Technologies, Inc. Method for Improving Health Outcomes
JP6335337B2 (ja) 2014-02-21 2018-05-30 アヴァディム・テクノロジーズ，インコーポレイテッド 尿道カテーテルの維持のための方法
JP2017534689A (ja) 2014-11-19 2017-11-24 アヴァディム・テクノロジーズ，インコーポレイテッド ざ瘡の予防および治療のための方法
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法
CA3143518A1 (en) 2019-06-12 2020-12-17 Avadim Health Ip, Inc. Compositions and methods for the antiseptic cleansing and biofilms treatment of mammalian tissue

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US24906A (en) * 1859-07-26 Simeon goodfellow
USRE24906E (en) 1955-11-18 1960-12-13 Pressure-sensitive adhesive sheet material
US3700674A (en) * 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
US4013665A (en) * 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4052393A (en) * 1975-11-03 1977-10-04 E. R. Squibb & Sons, Inc. 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters
US4197403A (en) * 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4191767A (en) * 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
DE3364438D1 (en) 1982-10-18 1986-08-14 Pfizer Triazoloquinoxalines as antidepressants and antifatigue agents
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
CA1263378A (en) 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinolines useful as immunomodulating agents
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
WO1988009676A1 (en) 1987-06-01 1988-12-15 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
JP2955019B2 (ja) 1991-03-01 1999-10-04 ミネソタ マイニング アンド マニュファクチャリング カンパニー １−置換、２−置換１Ｈ−イミダゾ〔４，５−ｃ〕キノリン−４−アミン
ES2149276T3 (es) * 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
CZ294563B6 (cs) 1996-10-25 2005-02-16 Minnesota Mining And Manufacturing Company Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0877089A1 (en) 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI1040112T1 (en) 1997-12-11 2005-02-28 Minnesota Mining And Manufacturing Company Imidazonaphthyridines and their use in inducing cytokine biosynthesis
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
HU229441B1 (en) * 1999-01-08 2013-12-30 3M Innovative Properties Co Formulations and methods for treating mucosal associated conditions with an immune response modifier
RU2143900C1 (ru) * 1999-03-31 2000-01-10 Институт цитологии и генетики СО РАН Способ получения изониазида пролонгированного действия
DE19941509A1 (de) * 1999-08-31 2001-03-29 Interconnectron Ges Fuer Ind S Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen
US6464937B2 (en) * 2000-11-01 2002-10-15 Pml Microbiologicals, Inc. Ultrapure sterilization of microbiological test media by electron beam irradiation
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
ATE556711T1 (de) * 2003-03-13 2012-05-15 3M Innovative Properties Co Verfahren zur verbesserung der hautqualität
WO2005020995A1 (en) 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1602365A1 (en) * 2004-03-03 2005-12-07 Switch Biotech Aktiengesellschaft Pharmaceutical composition for topical use in form of xerogels or films and methods for production
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine

Also Published As

Publication number Publication date
HRP20120128T1 (hr) 2012-03-31
NO338958B1 (no) 2016-11-07
RS20070318A (sr) 2009-05-06
UA93496C2 (uk) 2011-02-25
CY1112264T1 (el) 2015-12-09
AU2007279376A1 (en) 2008-02-07
CA2659733A1 (en) 2008-02-07
EP1891953A1 (en) 2008-02-27
ATE532511T1 (de) 2011-11-15
WO2008016475A2 (en) 2008-02-07
ZA200900618B (en) 2010-03-31
IL184652A0 (en) 2008-01-20
DK1891953T3 (da) 2012-02-27
PL1891953T3 (pl) 2012-04-30
RU2474425C2 (ru) 2013-02-10
ES2375744T3 (es) 2012-03-05
CL2007002228A1 (es) 2008-01-18
US20100096287A1 (en) 2010-04-22
US8124096B2 (en) 2012-02-28
AU2007279376B2 (en) 2012-09-06
EP1891953B1 (en) 2011-11-09
PT1891953E (pt) 2012-01-24
UY30513A1 (es) 2008-02-29
WO2008016475A3 (en) 2008-11-20
SI1891953T1 (sl) 2012-05-31
PE20080523A1 (es) 2008-07-13
RS52120B (sr) 2012-08-31
IL184652A (en) 2014-02-27
NO20073913L (no) 2008-02-01
RU2007129104A (ru) 2009-02-10
AR062121A1 (es) 2008-10-15

Similar Documents

Publication Publication Date Title
MEP20608A (hr) Sterilne formulacije modifikatora imunskog odgovora i postupci dobijanja
CY1118370T1 (el) 4-(8-μεθοξυ-1-((1-μεθοξυπροπαν-2-υλ)-2(τετραϋδρο-2η-πυραν-4-υλ)-1η-ιμιδαζο[4,5-c]κινολιν-7-υλ)-3,5-διμεθυλισοξαζολιο και χρηση αυτου ως αναστολεας βρωμοπεδιο
PE20100469A1 (es) Formulaciones de imiquimod
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
BR112012018670A2 (pt) combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
NO20090610L (no) Faste preparater omfattende tadalafil og minst en baerer
TN2011000626A1 (en) 1h-imidazo[4,5-c]quinolinone derivatives
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
BRPI1012697A2 (pt) derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
GEP20146049B (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin- 2-one lactate monohydrate
UA101339C2 (ru) Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
Abuzeid et al. Antimycobacterial activity of selected medicinal plants traditionally used in Sudan to treat infectious diseases
CR20120068A (es) Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales
NZ718163A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MX2012013606A (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
WO2013192517A3 (en) Compounds for treating infectious diseases
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
Faria et al. Influence of the vehicle and antibiotic formulation on cytotoxicity of triple antibiotic paste
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
BRPI0913297B8 (pt) composição farmacêutica estabilizada
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
EP2134712A4 (en) ASPARTATE FROM 1-CYCLOPROPYL-6-FLUOR-7- (8-METHOXYIMINO-2,6-DIAZA-SPIRO [3.4] OCT-6-YL) -4-OXO-1,4-DIHYDRO- [1,8] NAPHTHYRIDINE -3-CARBOXYLIC ACID, METHOD FOR THE PRODUCTION THEREOF AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION THEREWITH
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon